dapoxetine
Phase 3- Indications
- Premature ejaculation
Company intelligence / Profile preview
Prior to acquisition, MRLI was one of the largest global central laboratory providers supporting Phase I-IV clinical studies in cholesterol, endocrine, metabolic and cardiovascular research. It was recognized for standardized efficacy and safety testing in pharmaceutical clinical development. The company operated accredited labs in the US and Belgium with approximately 235 professionals at time of acquisition by PPD in early 2003.
After acquisition by PPD (Pharmaceutical Product Development LLC), it continued as part of PPD's global central lab operations.
No independent pipeline or clinical results as it did not develop therapeutics itself.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Medical Research Laboratories International.